NO20061978L - Imidazopyridinsubstituerte tropanderivater med CCR5-reseptorantagonist aktivitet for behandling av HIV og inflammasjon - Google Patents
Imidazopyridinsubstituerte tropanderivater med CCR5-reseptorantagonist aktivitet for behandling av HIV og inflammasjonInfo
- Publication number
- NO20061978L NO20061978L NO20061978A NO20061978A NO20061978L NO 20061978 L NO20061978 L NO 20061978L NO 20061978 A NO20061978 A NO 20061978A NO 20061978 A NO20061978 A NO 20061978A NO 20061978 L NO20061978 L NO 20061978L
- Authority
- NO
- Norway
- Prior art keywords
- treatment
- hiv
- imidazopyridine
- inflammation
- receptor antagonist
- Prior art date
Links
- 230000000694 effects Effects 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 title 1
- 239000003067 chemokine receptor CCR5 antagonist Substances 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 150000003813 tropane derivatives Chemical class 0.000 title 1
- 102000004274 CCR5 Receptors Human genes 0.000 abstract 2
- 108010017088 CCR5 Receptors Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 241001430294 unidentified retrovirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
Abstract
Foreliggende oppfinnelse tilveiebringer forbindelser med formel (I) hvori R1 og R2 er som definert ovenfor. Forbindelsene ifølge oppfinnelsen er modulatorer, særlig antagonister av aktiviteten til kjemokin CCR5-reseptorer. Modulatorer av CCR5-reseptoren kan være anvendelig ved behandling av forskjellige inflammasjonssykdommer og tilstander og ved behandling av infeksjon ved HIV og genetisk relaterte retroviruser.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0323236.0A GB0323236D0 (en) | 2003-10-03 | 2003-10-03 | Chemical compounds |
| GB0325020A GB0325020D0 (en) | 2003-10-27 | 2003-10-27 | Chemical compounds |
| GB0418566A GB0418566D0 (en) | 2004-08-19 | 2004-08-19 | Tropane derivatives |
| PCT/IB2004/003153 WO2005033107A1 (en) | 2003-10-03 | 2004-09-28 | Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20061978L true NO20061978L (no) | 2006-07-03 |
Family
ID=34426592
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20061978A NO20061978L (no) | 2003-10-03 | 2006-05-03 | Imidazopyridinsubstituerte tropanderivater med CCR5-reseptorantagonist aktivitet for behandling av HIV og inflammasjon |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US7309790B2 (no) |
| EP (1) | EP1682545B1 (no) |
| JP (1) | JP4874107B2 (no) |
| KR (1) | KR100777885B1 (no) |
| AP (1) | AP2174A (no) |
| AR (1) | AR045856A1 (no) |
| AT (1) | ATE380813T1 (no) |
| AU (1) | AU2004278158B2 (no) |
| BR (1) | BRPI0414862A (no) |
| CA (1) | CA2540834C (no) |
| CY (1) | CY1107281T1 (no) |
| DE (1) | DE602004010708T2 (no) |
| DK (1) | DK1682545T3 (no) |
| EA (1) | EA009941B1 (no) |
| EC (1) | ECSP066475A (no) |
| ES (1) | ES2295924T3 (no) |
| GE (1) | GEP20084417B (no) |
| HN (1) | HN2004000383A (no) |
| HR (1) | HRP20080052T3 (no) |
| IL (1) | IL174208A0 (no) |
| MA (1) | MA28080A1 (no) |
| MX (1) | MXPA06003749A (no) |
| MY (1) | MY137609A (no) |
| NO (1) | NO20061978L (no) |
| NZ (1) | NZ545837A (no) |
| OA (1) | OA13266A (no) |
| PA (1) | PA8614301A1 (no) |
| PE (1) | PE20050961A1 (no) |
| PL (1) | PL1682545T3 (no) |
| PT (1) | PT1682545E (no) |
| RS (1) | RS20060198A (no) |
| SI (1) | SI1682545T1 (no) |
| TW (1) | TWI280244B (no) |
| UY (1) | UY28546A1 (no) |
| WO (1) | WO2005033107A1 (no) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20030762A1 (es) | 2001-12-18 | 2003-09-05 | Schering Corp | Compuestos heterociclicos como antagonistas nk1 |
| TWI329105B (en) | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7122542B2 (en) | 2003-07-30 | 2006-10-17 | Rigel Pharmaceuticals, Inc. | Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds |
| US20070203161A1 (en) | 2006-02-24 | 2007-08-30 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| RU2485106C2 (ru) | 2005-06-08 | 2013-06-20 | Райджел Фамэсьютикэлз, Инк. | Соединения, проявляющие активность в отношении jak-киназы (варианты), способ лечения заболеваний, опосредованных jak-киназой, способ ингибирования активности jak-киназы (варианты), фармацевтическая композиция на основе указанных соединений |
| US8962643B2 (en) | 2006-02-24 | 2015-02-24 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the JAK pathway |
| ES2553805T3 (es) | 2006-04-05 | 2015-12-11 | Opko Health, Inc. | Formulaciones farmacéuticas que comprenden sales de (5S,8S)-8-[{(1R)-1-(3,5-bis-(trifluorometil)fenil]-etoxi}-metil]-8-fenil-1,7-diazaespiro[4.5]decan-2-ona y su utilización médica |
| WO2008030853A2 (en) * | 2006-09-06 | 2008-03-13 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| CA2673125C (en) | 2006-10-19 | 2015-04-21 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| US20090325936A1 (en) * | 2006-12-20 | 2009-12-31 | Bilodeau Mark T | Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases |
| PE20081891A1 (es) * | 2007-03-22 | 2008-12-27 | Opko Health Inc | Formulaciones de comprimidos que contienen sales de 8-[{1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diaza-spiro[4.5]decan-2-ona y comprimidos elaborados a partir de estas |
| SI2074120T1 (sl) * | 2007-10-25 | 2010-06-30 | Exelixis Inc | Tropan spojine |
| HRP20170317T1 (hr) | 2008-02-15 | 2017-04-21 | Rigel Pharmaceuticals, Inc. | Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza |
| PT2323993E (pt) | 2008-04-16 | 2015-10-12 | Portola Pharm Inc | 2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| US8258144B2 (en) | 2008-04-22 | 2012-09-04 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| SG157299A1 (en) | 2008-05-09 | 2009-12-29 | Agency Science Tech & Res | Diagnosis and treatment of kawasaki disease |
| CN105503870A (zh) | 2009-08-14 | 2016-04-20 | 欧科生医股份有限公司 | 神经激肽-1拮抗剂的静脉内制剂 |
| PE20130529A1 (es) | 2010-04-02 | 2013-05-14 | Phivco 1 Llc | Terapia de combinacion que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinetico |
| EP2975027A1 (en) | 2010-11-01 | 2016-01-20 | Portola Pharmaceuticals, Inc. | Nicotinamides as jak kinase modulators |
| EP2741777B1 (en) | 2011-08-12 | 2017-01-18 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| US8877760B2 (en) | 2011-11-23 | 2014-11-04 | Portola Pharmaceuticals, Inc. | Substituted pyrazine-2-carboxamide kinase inhibitors |
| EP2903970A4 (en) | 2012-10-08 | 2016-11-30 | Portola Pharm Inc | SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS |
| AU2014326601B2 (en) * | 2013-09-25 | 2018-01-18 | SpecGx LLC | Preparation of radioiodinated 3-fluoropropyl-nor-beta-CIT |
| GB201321748D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
| WO2023192360A1 (en) * | 2022-03-31 | 2023-10-05 | Incelldx, Inc. | Methods of treating a subject for post-treatment lyme disease (ptld) and compositions for use in the same |
| WO2023192361A1 (en) * | 2022-03-31 | 2023-10-05 | Incelldx, Inc. | Methods of treating a subject for fibromyalgia and compositions for use in the same |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| JP2899418B2 (ja) | 1994-04-19 | 1999-06-02 | ノイロサーチ アクティーゼルスカブ | トロパン誘導体、それらの製造及び用途 |
| GB9518953D0 (en) * | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| ZA971525B (en) | 1996-02-22 | 1997-10-21 | Neurosearch As | Tropane derivatives, their preparation and use. |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| PE20001420A1 (es) * | 1998-12-23 | 2000-12-18 | Pfizer | Moduladores de ccr5 |
| ES2215129T3 (es) | 2000-05-26 | 2004-10-01 | Pfizer Inc. | Derivados de triazolil tropano como modulares de ccr5. |
| US6855724B2 (en) * | 2002-04-08 | 2005-02-15 | Agouron Pharmaceuticals, Inc. | Tropane derivatives useful in therapy |
| OA12798A (en) * | 2002-04-08 | 2006-07-10 | Pfizer | Tropane derivatives as CCR5 modulators. |
-
2004
- 2004-09-28 AP AP2006003580A patent/AP2174A/xx active
- 2004-09-28 CA CA2540834A patent/CA2540834C/en not_active Expired - Fee Related
- 2004-09-28 PL PL04769496T patent/PL1682545T3/pl unknown
- 2004-09-28 DK DK04769496T patent/DK1682545T3/da active
- 2004-09-28 SI SI200430564T patent/SI1682545T1/sl unknown
- 2004-09-28 HR HR20080052T patent/HRP20080052T3/xx unknown
- 2004-09-28 KR KR1020067006293A patent/KR100777885B1/ko not_active Expired - Fee Related
- 2004-09-28 DE DE602004010708T patent/DE602004010708T2/de not_active Expired - Lifetime
- 2004-09-28 MX MXPA06003749A patent/MXPA06003749A/es active IP Right Grant
- 2004-09-28 ES ES04769496T patent/ES2295924T3/es not_active Expired - Lifetime
- 2004-09-28 BR BRPI0414862-2A patent/BRPI0414862A/pt not_active IP Right Cessation
- 2004-09-28 EA EA200600480A patent/EA009941B1/ru not_active IP Right Cessation
- 2004-09-28 US US10/953,136 patent/US7309790B2/en not_active Expired - Fee Related
- 2004-09-28 WO PCT/IB2004/003153 patent/WO2005033107A1/en not_active Ceased
- 2004-09-28 AU AU2004278158A patent/AU2004278158B2/en not_active Ceased
- 2004-09-28 NZ NZ545837A patent/NZ545837A/en not_active IP Right Cessation
- 2004-09-28 RS YUP-2006/0198A patent/RS20060198A/sr unknown
- 2004-09-28 GE GEAP20049330A patent/GEP20084417B/en unknown
- 2004-09-28 AT AT04769496T patent/ATE380813T1/de active
- 2004-09-28 PT PT04769496T patent/PT1682545E/pt unknown
- 2004-09-28 JP JP2006530737A patent/JP4874107B2/ja not_active Expired - Fee Related
- 2004-09-28 EP EP04769496A patent/EP1682545B1/en not_active Expired - Lifetime
- 2004-09-28 OA OA1200600114A patent/OA13266A/en unknown
- 2004-09-29 HN HN2004000383A patent/HN2004000383A/es unknown
- 2004-09-29 TW TW093129475A patent/TWI280244B/zh not_active IP Right Cessation
- 2004-10-01 MY MYPI20044043A patent/MY137609A/en unknown
- 2004-10-01 AR ARP040103581A patent/AR045856A1/es not_active Application Discontinuation
- 2004-10-01 PE PE2004000965A patent/PE20050961A1/es not_active Application Discontinuation
- 2004-10-01 PA PA20048614301A patent/PA8614301A1/es unknown
- 2004-10-01 UY UY28546A patent/UY28546A1/es unknown
-
2006
- 2006-03-09 IL IL174208A patent/IL174208A0/en unknown
- 2006-04-03 EC EC2006006475A patent/ECSP066475A/es unknown
- 2006-04-03 MA MA28906A patent/MA28080A1/fr unknown
- 2006-05-03 NO NO20061978A patent/NO20061978L/no not_active Application Discontinuation
-
2007
- 2007-08-27 US US11/845,500 patent/US7790740B2/en not_active Expired - Fee Related
-
2008
- 2008-02-14 CY CY20081100178T patent/CY1107281T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20061978L (no) | Imidazopyridinsubstituerte tropanderivater med CCR5-reseptorantagonist aktivitet for behandling av HIV og inflammasjon | |
| MY134223A (en) | Tropane derivatives as ccr5 modulators | |
| WO2007116313A3 (en) | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors | |
| NO20044731L (no) | Kinolin- og isokinolinderivater fremgangsmate for fremstilling derav og anvendelse derav som betennelseshemmere | |
| NO20070489L (no) | 3-aminocyklopentankarboksamider som modulatorer av kjemokinreseptorer. | |
| NO20022857L (no) | Nye P2X7-reseptoragonister for bruk i behandling av inflammatoriske, immun- eller kardiovaskul¶re sykdommer | |
| NO20080408L (no) | Azaindazolforbindelser og anvendelse derav | |
| NO20075059L (no) | Nye forbindelser II 2-pyridinderivater som inhibitorer av neutrofil elastase | |
| NO20091409L (no) | Pyridin-3-yl-derivater som immunmodulerende midler | |
| NO20054220L (no) | Substituerte N-arylheterocykler, fremgangsmate for fremstilling derav og deres anvendelse som legemiddel | |
| NO20044826L (no) | Pyrrolidinderivater | |
| GEP20084505B (en) | 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors | |
| NO20070532L (no) | Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer | |
| NO20070137L (no) | Heterocykliske antivirale forbindelser | |
| NO20062677L (no) | Benzyleteraminforbindelser anvendbare som CCR-5-antagonister | |
| EA200700117A1 (ru) | N-замещенные пиперидины и их применение в качестве фармацевтических препаратов | |
| TW200635897A (en) | Piperidine derivatives and their use as anti-inflammatory agents | |
| NO20092689L (no) | Quinuclidinolderivater som muskarin reseptorantagonister | |
| ATE418548T1 (de) | Substituierte 3-cyanothiophen acetamide als glucagon receptor antagonisten | |
| NO20071574L (no) | Arylsulfonylstilbenderivater for behandling av insomni og beslektede tilstander. | |
| NO20020282D0 (no) | Nytt difenylpiperidinderivat | |
| NO20062021L (no) | Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika | |
| NO20083070L (no) | Nye N-(fluor-pyrazinyl)-fenylsulfonamidler som modulatorer av kemokin-reseptor CCR4 | |
| NO20071111L (no) | Kynurensyreamidderivater som NR2B-reseptorantagonister | |
| DK1673354T3 (da) | Arylindenopyridiner og arylindenopyrimidiner og deres anvendelse som adenosin-A2a-receptorantagonister |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |